Catalent is investing $9 million in a new clinical supply facility in San Diego, scheduled to open in the summer of 2020.

The new 24,257 sq.-ft. facility will offer full clinical supply services to pharmaceutical and biopharmaceutical customers and will specialize in services for early-phase clinical trials. Its capabilities will include clinical supply management, primary and secondary packaging, complex labeling services, clinical storage, distribution, and drug returns and destruction, and will include stability chambers.

Located near the company’s West Coast early-phase oral drug product development center, the new facility expands Catalent’s OptiForm Total Supply service, offering integrated development, clinical supply manufacturing and distribution, which aims to minimize overall project risks and reduce the time taken to move a program from development into clinic.

“This investment supports Catalent’s commitment to offering customers greater flexibility and expanded support for early-phase studies” commented Paul Hegwood, President, Clinical Supply Services. “The facility will allow Catalent to provide superior clinical services throughout the western corridor of the U.S. and Canada’s drug development region.”